Advances and challenges in hemophilic arthropathy

Seminars in Hematology

Volumn 53, Issue 1, 2016, Pages 10-19

  Wyseure, Tine ^a   Mosnier, Laurent O ^a   von Drygalski, Annette ^a,b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Arthropathy; Biomarkers; Hemarthrosis; Hemophilia; Imaging

Indexed keywords

ALPHA 2 ANTIPLASMIN; BIOLOGICAL MARKER; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CHONDROITIN SULFATE; CHONDROITIN SULFATE 846; COLLAGEN TYPE 2; GLYCOSAMINOGLYCAN; HEMOGLOBIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; UNCLASSIFIED DRUG; UROKINASE; VASCULOTROPIN;

CARTILAGE DEGENERATION; DISEASE ACTIVITY; DOPPLER FLOWMETRY; ECHOGRAPHY; FIBRIN DEPOSITION; FIBRINOLYSIS; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIC ARTHROPATHY; HUMAN; HYPERTROPHY; IRON STORAGE; JOINT DESTRUCTION; JOINT RADIOGRAPHY; MUSCULOSKELETAL ULTRASOUND; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; POINT OF CARE TESTING; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYNOVIAL HYPERTROPHY; SYNOVITIS; SYNOVIUM; ANIMAL; BLOOD; CARTILAGE; COMPLICATION; HEMOPHILIA A; PATHOLOGY;

ANIMALS; BIOMARKERS; CARTILAGE; HEMOPHILIA A; HUMANS; HYPERTROPHY; SYNOVITIS;

EID: 84957580144     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2015.10.005     Document Type: Review

References (114)

1. Berntorp E., Shapiro A.D. Modern haemophilia care. Lancet 2012, 379:1447-1456.
2. Soucie J.M., Cianfrini C., Janco R.L., et al. Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood 2004, 103:2467-2473.
3. Aledort L.M., Haschmeyer R.H., Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med. 1994, 236:391-399.
4. Oldenburg J., Zimmermann R., Katsarou O., et al. Controlled, cross-sectional MRI evaluation of joint status in severe haemophilia A patients treated with prophylaxis vs. on demand. Haemophilia 2015, 21:171-179.
5. Fischer K., Steen Carlsson K., Petrini P., et al. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood 2013, 122:1129-1136.
6. Jackson S.C., Yang M., Minuk L., et al. Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions. BMC Hematol 2015, 15:4.
7. Aznar J.A., Lucia F., Abad-Franch L., et al. Haemophilia in Spain. Haemophilia 2009, 15:665-675.
8. Schramm W., Gringeri A., Ljung R., et al. Haemophilia care in Europe: the ESCHQoL study. Haemophilia 2012, 18:729-737.
9. Baumgardner J., Elon L., Antun A., et al. Physical activity and functional abilities in adult males with haemophilia: a cross-sectional survey from a single US haemophilia treatment centre. Haemophilia 2013, 19:551-557.
10. You C.W. The impact of haemarthropathy on the QoL of Korean severe haemophilia A patients: the critical level of haemarthropathy for the QoL. Haemophilia 2013, 19:637-641.
11. Darby S.C., Kan S.W., Spooner R.J., et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007, 110:815-825.
12. Rodriguez-Merchan E.C. Haemophilic synovitis of the elbow: radiosynovectomy, open synovectomy or arthroscopic synovectomy?. Thromb Res 2013, 132:15-18.
13. Galli E., Baques A., Moretti N., Candela M., Caviglia H. Hemophilic chronic synovitis: therapy of hemarthrosis using endovascular embolization of knee and elbow arteries. Cardiovasc Intervent Radiol 2013, 36:964-969.
14. Vanderhave K.L., Caird M.S., Hake M., et al. Musculoskeletal care of the hemophiliac patient. J Am Acad Orthop Surg. 2012, 20:553-563.
15. Rodriguez-Merchan E.C. Aspects of current management: orthopaedic surgery in haemophilia. Haemophilia 2012, 18:8-16.
16. Key J.A. Hemophilic Arthritis: Bleeder's Joints. Ann Surg 1932, 95:198-225.
17. Kilcoyne R.F., Lundin B., Pettersson H. Evolution of the imaging tests in hemophilia with emphasis on radiography and magnetic resonance imaging. Acta Radiol 2006, 47:287-296.
18. Arnold W.D., Hilgartner M.W. Hemophilic arthropathy. Current concepts of pathogenesis and management. J Bone Joint Surg Am 1977, 59:287-305.
19. Pettersson H., Ahlberg A., Nilsson I.M. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res 1980, 153-159.
20. Nilsson I.M., Berntorp E., Lofqvist T., Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J. Intern Med 1992, 232:25-32.
21. Feldman B.M., Funk S., Lundin B., Doria A.S., Ljung R., Blanchette V. Musculoskeletal measurement tools from the International Prophylaxis Study Group (IPSG). Haemophilia 2008, 14(Suppl 3):162-169.
22. Chan M.W., Leckie A., Xavier F., et al. A systematic review of MR imaging as a tool for evaluating haemophilic arthropathy in children. Haemophilia 2013, 19:e324-e334.
23. Jelbert A., Vaidya S., Fotiadis N. Imaging and staging of haemophilic arthropathy. Clin Radiol 2009, 64:1119-1128.
24. Lundin B., Manco-Johnson M.L., Ignas D.M., et al. An MRI scale for assessment of haemophilic arthropathy from the International Prophylaxis Study Group. Haemophilia 2012, 18:962-970.
25. Ceponis A., Wong-Sefidan I., Glass C.S., von Drygalski A. Rapid musculoskeletal ultrasound for painful episodes in adult haemophilia patients. Haemophilia 2013, 19:790-798.
26. Kidder W., Nguyen S., Larios J., Bergstrom J., Ceponis A., von Drygalski A. Point-of-care musculoskeletal ultrasound is critical for the diagnosis of hemarthroses, inflammation and soft tissue abnormalities in adult patients with painful haemophilic arthropathy. Haemophilia 2015.
27. Aznar J.A., Abad-Franch L., Perez-Alenda S., Haya S., Cid A.R., Querol F. Ultrasonography in the monitoring of management of haemarthrosis. Haemophilia 2011, 17:826-828.
28. Aznar J.A., Perez-Alenda S., Jaca M., et al. Home-delivered ultrasound monitoring for home treatment of haemarthrosis in haemophilia A. Haemophilia 2015, 21:e147-e150.
29. Jacobson J.A. Musculoskeletal ultrasound: focused impact on MRI. AJR Am J Roentgenol 2009, 193:619-627.
30. Wittoek R., Jans L., Lambrecht V., Carron P., Verstraete K., Verbruggen G. Reliability and construct validity of ultrasonography of soft tissue and destructive changes in erosive osteoarthritis of the interphalangeal finger joints: a comparison with MRI. Ann Rheum Dis 2011, 70:278-283.
31. Shanbhogue A.K., Sandhu M.S., Singh P., Ojili V., Khandelwal N., Sen R. Real time spatial compound ultrasound in the evaluation of meniscal injuries: a comparison study with conventional ultrasound and MRI. Knee 2009, 16:191-195.
32. Doria A.S., Keshava S.N., Mohanta A., et al. Diagnostic accuracy of ultrasound for assessment of hemophilic arthropathy: MRI correlation. AJR Am J Roentgenol 2015, 204:W336-W347.
33. Acharya S.S., Schloss R., Dyke J.P., et al. Power Doppler sonography in the diagnosis of hemophilic synovitis-a promising tool. J Thromb Haemost 2008, 6:2055-2061.
34. Sierra Aisa C., Lucia Cuesta J.F., Rubio Martinez A., et al. Comparison of ultrasound and magnetic resonance imaging for diagnosis and follow-up of joint lesions in patients with haemophilia. Haemophilia 2014, 20:e51-e57.
35. Melchiorre D., Linari S., Innocenti M., et al. Ultrasound detects joint damage and bleeding in haemophilic arthropathy: a proposal of a score. Haemophilia 2011, 17:112-117.
36. Rowbotham E.L., Grainger A.J. Rheumatoid arthritis: ultrasound versus MRI. AJR Am J Roentgenol 2011, 197:541-546.
37. Porta F., Radunovic G., Vlad V., et al. The role of Doppler ultrasound in rheumatic diseases. Rheumatology 2012, 51:976-982.
38. Bhat V., Olmer M., Joshi S., et al. Vascular remodeling underlies re-bleeding in hemophilic arthropathy. Am J Hematol 2015, 90(11):1027-1035.
39. Moore C.L., Copel J.A. Point-of-care ultrasonography. N Engl J Med 2011, 364:749-757.
40. McAlindon T., Kissin E., Nazarian L., et al. American College of Rheumatology report on reasonable use of musculoskeletal ultrasonography in rheumatology clinical practice. Arthritis Care Res 2012, 64:1625-1640.
41. Solomon S.D., Saldana F. Point-of-care ultrasound in medical education-stop listening and look. N Engl J Med 2014, 370:1083-1085.
42. Muca-Perja M., Riva S., Grochowska B., Mangiafico L., Mago D., Gringeri A. Ultrasonography of haemophilic arthropathy. Haemophilia 2012, 18:364-368.
43. Martinoli C., Della Casa Alberighi O., Di Minno G., et al. Development and definition of a simplified scanning procedure and scoring method for Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US). Thromb Haemost 2013, 109:1170-1179.
44. Attur M., Krasnokutsky-Samuels S., Samuels J., Abramson S.B. Prognostic biomarkers in osteoarthritis. Curr Opin Rheumatol 2013, 25:136-144.
45. Jameson J.L., Longo D.L. Precision medicine-personalized, problematic, and promising. N Engl J Med 2015, 372:2229-2234.
46. Jansen N.W., Roosendaal G., Lundin B., et al. The combination of the biomarkers urinary C-terminal telopeptide of type II collagen, serum cartilage oligomeric matrix protein, and serum chondroitin sulfate 846 reflects cartilage damage in hemophilic arthropathy. Arthritis Rheum 2009, 60:290-298.
47. van Vulpen L.F., van Meegeren M.E., Roosendaal G., et al. Biochemical markers of joint tissue damage increase shortly after a joint bleed; an explorative human and canine in vivo study. Osteoarthritis Cartilage 2015, 23:63-69.
48. Kraus V.B. Osteoarthritis year 2010 in review: biochemical markers. Osteoarthritis Cartilage 2011, 19:346-353.
49. Lotz M., Martel-Pelletier J., Christiansen C., et al. Value of biomarkers in osteoarthritis: current status and perspectives. Ann Rheum Dis 2013, 72:1756-1763.
50. Bay-Jensen A.C., Sondergaard B.C., Christiansen C., Karsdal M.A., Madsen S.H., Qvist P. Biochemical markers of joint tissue turnover. Assay Drug Dev Technol 2010, 8:118-124.
51. Karsdal M.A., Henriksen K., Leeming D.J., et al. Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers 2009, 14:181-202.
52. Manzo A., Bombardieri M., Humby F., Pitzalis C. Secondary and ectopic lymphoid tissue responses in rheumatoid arthritis: from inflammation to autoimmunity and tissue damage/remodeling. Immunol Rev 2010, 233:267-285.
53. Rooney T., Roux-Lombard P., Veale D.J., FitzGerald O., Dayer J.M., Bresnihan B. Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression: analysis of a proof-of-concept randomised clinical trial of cytokine blockade. Ann Rheum Dis 2010, 69:706-714.
54. Bugatti S., Manzo A., Bombardieri M., et al. Synovial tissue heterogeneity and peripheral blood biomarkers. Curr Rheumatol Rep 2011, 13:440-448.
55. van Riel P.L. The development of the disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28). Clin Exp Rheumatol 2014, 32:S-65-S-74.
56. Senolt L., Grassi W., Szodoray P. Laboratory biomarkers or imaging in the diagnostics of rheumatoid arthritis?. BMC Med 2014, 12:49.
57. Zukotynski K., Jarrin J., Babyn P.S., et al. Sonography for assessment of haemophilic arthropathy in children: a systematic protocol. Haemophilia 2007, 13:293-304.
58. Doria A.S., Babyn P.S., Lundin B., et al. Reliability and construct validity of the compatible MRI scoring system for evaluation of haemophilic knees and ankles of haemophilic children. Expert MRI working group of the International Prophylaxis Study Group. Haemophilia 2006, 12:503-513.
59. Nuss R., Kilcoyne R.F., Rivard G.E., Murphy J. Late clinical, plain X-ray and magnetic resonance imaging findings in haemophilic joints treated with radiosynoviorthesis. Haemophilia 2000, 6:658-663.
60. Acharya S.S., Kaplan R.N., Macdonald D., Fabiyi O.T., DiMichele D., Lyden D. Neoangiogenesis contributes to the development of hemophilic synovitis. Blood 2011, 117:2484-2493.
61. Yuan Q., Sun L., Li J.J., An C.H. Elevated VEGF levels contribute to the pathogenesis of osteoarthritis. BMC Musculoskelet Disord 2014, 15:437.
62. Azizi G., Boghozian R., Mirshafiey A. The potential role of angiogenic factors in rheumatoid arthritis. Int J Rheum Dis 2014, 17:369-383.
63. Ballara S., Taylor P.C., Reusch P., et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 2001, 44:2055-2064.
64. Mapp P.I., Walsh D.A. Mechanisms and targets of angiogenesis and nerve growth in osteoarthritis. Nat Rev Rheumatol 2012, 8:390-398.
65. Valentino L.A. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy. J Thromb Haemost. 2010, 8:1895-1902.
66. Franchini M., Lippi G. Factor V Leiden and hemophilia. Thromb Res 2010, Vol 125:119-123. United States: 2009 Elsevier Ltd.
67. Valentino L.A., Hakobyan N., Enockson C., et al. Exploring the biological basis of haemophilic joint disease: experimental studies. Haemophilia 2012, 18:310-318.
68. Rodriguez-Merchan E.C. Pathogenesis, early diagnosis, and prophylaxis for chronic hemophilic synovitis. Clin Orthop Relat Res 1997, 6-11.
69. Hakobyan N., Enockson C., Cole A.A., Sumner D.R., Valentino L.A. Experimental haemophilic arthropathy in a mouse model of a massive haemarthrosis: gross, radiological and histological changes. Haemophilia 2008, 14:804-809.
70. Fabry G. Ultrastructural changes in synovium and cartilage in experimental hemarthrosis in dogs. Arch Orthop Trauma Surg 1990, 109:21-29.
71. Roy S., Ghadially F.N. Pathology of experimental haemarthrosis. Ann Rheum Dis 1966, 25:402-415.
72. Roosendaal G., Mauser-Bunschoten E.P., De Kleijn P., et al. Synovium in haemophilic arthropathy. Haemophilia 1998, 4:502-505.
73. Nieuwenhuizen L., Schutgens R.E., van Asbeck B.S., et al. Identification and expression of iron regulators in human synovium: evidence for upregulation in haemophilic arthropathy compared to rheumatoid arthritis, osteoarthritis, and healthy controls. Haemophilia 2013, 19:e218-e227.
74. Nieuwenhuizen L., Schutgens R.E., Coeleveld K., et al. Hemarthrosis in hemophilic mice results in alterations in M1-M2 monocyte/macrophage polarization. Thromb Res 2014, 133:390-395.
75. Hakobyan N., Kazarian T., Jabbar A.A., Jabbar K.J., Valentino L.A. Pathobiology of hemophilic synovitis I: overexpression of mdm2 oncogene. Blood 2004, 104:2060-2064.
76. Wen F.Q., Jabbar A.A., Chen Y.X., Kazarian T., Patel D.A., Valentino L.A. c-myc proto-oncogene expression in hemophilic synovitis: in vitro studies of the effects of iron and ceramide. Blood 2002, 100:912-916.
77. Roosendaal G., Vianen M.E., Wenting M.J., et al. Iron deposits and catabolic properties of synovial tissue from patients with haemophilia. J Bone Joint Surg Br 1998, 80:540-545.
78. Sen D., Chapla A., Walter N., Daniel V., Srivastava A., Jayandharan G.R. Nuclear factor (NF)-kappaB and its associated pathways are major molecular regulators of blood-induced joint damage in a murine model of hemophilia. J Thromb Haemost 2013, 11:293-306.
79. Ovlisen K., Kristensen A.T., Jensen A.L., Tranholm M. IL-1 beta, IL-6, KC and MCP-1 are elevated in synovial fluid from haemophilic mice with experimentally induced haemarthrosis. Haemophilia 2009, 15:802-810.
80. Narkbunnam N., Sun J., Hu G., et al. IL-6 receptor antagonist as adjunctive therapy with clotting factor replacement to protect against bleeding-induced arthropathy in hemophilia. J Thromb Haemost 2013, 11:881-893.
81. Jansen N.W., Roosendaal G., Hooiveld M.J., et al. Interleukin-10 protects against blood-induced joint damage. Br J Haematol 2008, 142:953-961.
82. van Meegeren M.E., Roosendaal G., Coeleveld K., Nieuwenhuizen L., Mastbergen S.C., Lafeber F.P. A single intra-articular injection with IL-4 plus IL-10 ameliorates blood-induced cartilage degeneration in haemophilic mice. Br J Haematol 2013, 160:515-520.
83. van Meegeren M.E., Roosendaal G., Jansen N.W., et al. IL-4 alone and in combination with IL-10 protects against blood-induced cartilage damage. Osteoarthritis Cartilage 2012, 20:764-772.
84. van Meegeren M.E., Roosendaal G., van Veghel K., Mastbergen S.C., Lafeber F.P. A short time window to profit from protection of blood-induced cartilage damage by IL-4 plus IL-10. Rheumatology 2013, 52:1563-1571.
85. Storti E., Magrini U., Ascari E. Synovial fibrinolysis and haemophilic haemarthrosis. Br Med J 1971, 4:812.
86. Pandolfi M., Ahlberg A., Traldi A., Nilsson I.M. Fibrinolytic activity of human synovial membranes in health and in haemophilia. Scand J Haematol 1972, 9:572-576.
87. Busso N., Peclat V., So A., Sappino A.P. Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints. Ann Rheum Dis 1997, 56:550-557.
88. Cole H.A., Ohba T., Nyman J.S., et al. Fibrin accumulation secondary to loss of plasmin-mediated fibrinolysis drives inflammatory osteoporosis in mice. Arthritis Rheumatol 2014, 66:2222-2233.
89. Weinberg J.B., Pippen A.M., Greenberg C.S. Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 1991, 34:996-1005.
90. So A.K., Varisco P.A., Kemkes-Matthes B., et al. Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. J Thromb Haemost 2003, 1:2510-2515.
91. Raghu H., Flick M.J. Targeting the coagulation factor fibrinogen for arthritis therapy. Curr Pharm Biotechnol 2011, 12:1497-1506.
92. Flick M.J., LaJeunesse C.M., Talmage K.E., et al. Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif. J Clin Invest 2007, 117:3224-3235.
93. Hvas A.M., Sorensen H.T., Norengaard L., Christiansen K., Ingerslev J., Sorensen B. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A. J Thromb Haemost 2007, 5:2408-2414.
94. Rainsford S.G., Jouhar A.J., Hall A. Tranexamic acid in the control of spontaneous bleeding in severe haemophilia. Thromb Diath Haemorrh 1973, 30:272-279.
95. Ronday H.K., Smits H.H., Van Muijen G.N., et al. Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Br J Rheumatol 1996, 35:416-423.
96. Judex M.O., Mueller B.M. Plasminogen activation/plasmin in rheumatoid arthritis: matrix degradation and more. Am J Pathol 2005, 166:645-647.
97. Nieuwenhuizen L., Roosendaal G., Coeleveld K., et al. Haemarthrosis stimulates the synovial fibrinolytic system in haemophilic mice. Thromb Haemost 2013, 110:173-183.
98. Nieuwenhuizen L., Roosendaal G., Mastbergen S.C., et al. Antiplasmin, but not amiloride, prevents synovitis and cartilage damage following hemarthrosis in hemophilic mice. J Thromb Haemost 2014, 12:237-245.
99. Kamper E.F., Kopeikina L.T., Trontzas P., Potamianou A., Tsiroglou E., Stavridis J.C. The effect of disease activity related cytokines on the fibrinolytic potential and cICAM-1 expression in rheumatoid arthritis. J Rheumatol 2000, 27:2545-2550.
100. Raghu H., Jone A., Cruz C., et al. Plasminogen is a joint-specific positive or negative determinant of arthritis pathogenesis in mice. Arthritis Rheumatol 2014, 66:1504-1516.
101. Broze G.J., Higuchi D.A. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 1996, 88:3815-3823.
102. Foley J.H., Nesheim M.E. Soluble thrombomodulin partially corrects the premature lysis defect in FVIII-deficient plasma by stimulating the activation of thrombin activatable fibrinolysis inhibitor. J Thromb Haemost 2009, 7:453-459.
103. Mosnier L.O., Lisman T., van den Berg H.M., Nieuwenhuis H.K., Meijers J.C., Bouma B.N. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost 2001, 86:1035-1039.
104. Myles T., Nishimura T., Yun T.H., et al. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003, 278:51059-51067.
105. Leung L.L., Nishimura T., Myles T. Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). Adv Exp Med Biol 2008, 632:61-69.
106. Lepus C.M., Song J.J., Wang Q., et al. Brief report: carboxypeptidase B serves as a protective mediator in osteoarthritis. Arthritis Rheumatol 2014, 66:101-106.
107. Sharif S.A., Du X., Myles T., et al. Thrombin-activatable carboxypeptidase B cleavage of osteopontin regulates neutrophil survival and synoviocyte binding in rheumatoid arthritis. Arthritis Rheum 2009, 60:2902-2912.
108. Song J.J., Hwang I., Cho K.H., et al. Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis. J Clin Invest 2011, 121:3517-3527.
109. Fabry G. Early changes in the ground substance of articular cartilage in experimental hemarthrosis in dogs, measured by the fixed-charge density method. Arch Orthop Trauma Surg 1989, 108:76-91.
110. Hoaglund F.T. Experimental hemarthrosis. The response of canine knees to injections of autologous blood. J Bone Joint Surg Am 1967, 49:285-298.
111. Roosendaal G., TeKoppele J.M., Vianen M.E., van den Berg H.M., Lafeber F.P., Bijlsma J.W. Blood-induced joint damage: a canine in vivo study. Arthritis Rheum 1999, 42:1033-1039.
112. Roosendaal G., Vianen M.E., van den Berg H.M., Lafeber F.P., Bijlsma J.W. Cartilage damage as a result of hemarthrosis in a human in vitro model. J Rheumatol 1997, 24:1350-1354.
113. Hooiveld M.J., Roosendaal G., van den Berg H.M., Bijlsma J.W., Lafeber F.P. Haemoglobin-derived iron-dependent hydroxyl radical formation in blood-induced joint damage: an in vitro study. Rheumatology 2003, 42:784-790.
114. Roosendaal G., Vianen M.E., Marx J.J., van den Berg H.M., Lafeber F.P., Bijlsma J.W. Blood-induced joint damage: a human in vitro study. Arthritis Rheum 1999, 42:1025-1032.